基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨

智通财经01-13

智通财经APP注意到，Beam Therapeutics (BEAM.US) 股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。该公司强调了其肝脏靶向基因疾病和血液学特许经营项目的近期进展，概述了 2026 年的战略重点，并指出预期的运营资金支持期限已得到延长，足以支持其各项计划。截至 ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2603575413?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-01-13 10:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603575413","market":"fut","top_or_hot":-1,"title":"基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨","media":"智通财经","content":"<div>\n<p>智通财经APP注意到，Beam Therapeutics (BEAM.US) 股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。该公司强调了其肝脏靶向基因疾病和血液学特许经营项目的近期进展，概述了 2026 年的战略重点，并指出预期的运营资金支持期限已得到延长，足以支持其各项计划。截至 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392020.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n基因药物开发取得进展 Beam Therapeutics (BEAM.US)股价大涨\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 10:16 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1392020.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP注意到，Beam Therapeutics (BEAM.US) 股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。该公司强调了其肝脏靶向基因疾病和血液学特许经营项目的近期进展，概述了 2026 年的战略重点，并指出预期的运营资金支持期限已得到延长，足以支持其各项计划。截至 ...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1392020.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4535","symbol_name":"淡马锡持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1392020.html","article_id":"2603575413","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603575413","pubTimestamp":1768270560,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP注意到，Beam Therapeutics  股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。截至 2025 年底，公司持有的现金、现金等价物及有价证券估值约为 12.5 亿美元;预计运营资金支持期限将延长至 2029 年，这将为 risto-cel 的预期上市以及 BEAM-302 关键开发计划的执行提供有力支持。此外，该公司肝脏靶向基因疾病特许经营项目的扩张正在进行中，","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4535":"淡马锡持仓","BK4611":"AI医疗","BK4139":"生物科技","BK4585":"ETF&股票定投概念","BEAM":"Beam Therapeutics, Inc.","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股","BK4588":"碎股","BK4556":"基因编辑","BK4505":"高瓴资本持仓"},"translate_title":"Progress in genetic drug development Beam Therapeutics (BEAM.US) stock surges","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BEAM":1.5,"LENZ":1.5},"content_text":"智通财经APP注意到，Beam Therapeutics (BEAM.US) 股价在周一大幅上涨超20%，截至收盘，该股涨22.29%，报33.69美元，此前该公司发布了关于持续致力于建立可持续、可预测模式以推进精准基因药物开发的最新进展。该公司强调了其肝脏靶向基因疾病和血液学特许经营项目的近期进展，概述了 2026 年的战略重点，并指出预期的运营资金支持期限已得到延长，足以支持其各项计划。截至 2025 年底，公司持有的现金、现金等价物及有价证券估值约为 12.5 亿美元;预计运营资金支持期限将延长至 2029 年，这将为 risto-cel 的预期上市以及 BEAM-302 关键开发计划的执行提供有力支持。此外，该公司肝脏靶向基因疾病特许经营项目的扩张正在进行中，","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603575413","isCrawlerRequest":true}